Harbin Medisan Pharmaceutical Co., Ltd. (SHE:002900)

SHE:002900 Revenue

Harbin Medisan Pharmaceutical had revenue of 194.34M CNY in the quarter ending September 30, 2026, with 16.00% growth. This brings the company's total for the last twelve months to 831.90M, down -4.88% year-over-year. In the year 2025, Harbin Medisan Pharmaceutical had annual revenue of 789.42M, down -30.29%. That makes Harbin Medisan Pharmaceutical the 21,033rd largest company in the world by revenue and 3,859th in China.

• Revenue (ttm): 831.90M
• Revenue Growth: -4.88%
• P/S Ratio: 3.79
• Revenue / Employee: 398.80K
• Employees: 2,086
• Market Cap: 3.15B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• North-East China 290.35M 36.8%
• East China 175.84M 22.3%
• Southern China 79.61M 10.1%
• Central China Region 78.98M 10.0%
• Northern China 75.98M 9.6%
• South-West 56.98M 7.2%
• Northwestern Region 20.86M 2.6%
• Overseas 10.81M 1.4%

Fiscal year ended Dec 31, 2025 See the full SHE:002900 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	789.42M	-343.05M	-30.29%
Dec 31, 2024	1.13B	-54.31M	-4.58%
Dec 31, 2023	1.19B	158.37M	15.40%
Jan 1, 2023	1.03B	82.61M	8.73%
Jan 1, 2022	945.80M	-393.08M	-29.36%

Data Source: S&P Global Market Intelligence Last updated: Oct 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 9, 2026

Data Sources Report a data error